ArticleAntimicrobial agents and chemotherapy2006
Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.Contemporary clinical trials · 2025Article
- Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement.Frontiers in cellular and infection microbiology · 2022Review
- A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Journal of clinical pharmacology · 2017Review
- Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.Drug design, development and therapy · 2016Article
- Eagle Effect in Nonreplicating Persister Mycobacteria.Antimicrobial agents and chemotherapy · 2015Article
- Involvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis.Antimicrobial agents and chemotherapy · 2015Article
- Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.American journal of respiratory and critical care medicine · 2013Article
- Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.Antimicrobial agents and chemotherapy · 2012Article
- Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.Antimicrobial agents and chemotherapy · 2011Article
- Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.Antimicrobial agents and chemotherapy · 2011Article
- Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.Antimicrobial agents and chemotherapy · 2011Article
- Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.Antimicrobial agents and chemotherapy · 2010Article
- Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2010Article
- Quinolones: action and resistance updated.Current topics in medicinal chemistry · 2009Review
- In vitro model of mycobacterial growth arrest using nitric oxide with limited air.Antimicrobial agents and chemotherapy · 2009Article
- Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.Antimicrobial agents and chemotherapy · 2008Article
- Quinolone-mediated bacterial death.Antimicrobial agents and chemotherapy · 2008Review
- Effect of anaerobic growth on quinolone lethality with Escherichia coli.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The C-8-methoxy fluoroquinolone moxifloxacin was more lethal against chloramphenicol-treated Mycobacterium tuberculosis than Bay y3114, a C-8-H cognate of moxifloxacin, and two C-8-methoxy fluoroquinolones, gatifloxacin and BMS-433368, which have different C-7 substituents. Thus, an optimal combination of C-7 and C-8 substituents is likely to be important for killing nongrowing M. tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.